- Home
- REFI vs ZURA Comparison
REFI vs ZURA Comparison
Compare REFI & ZURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | REFI | ZURA |
|---|---|---|
| Founded | 2021 | 2022 |
| Country | United States | United States |
| Employees | N/A | 30 |
| Industry | Real Estate Investment Trusts | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 255.6M | 521.8M |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | REFI | ZURA |
|---|---|---|
| Price | $11.20 | $5.84 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $11.78 |
| AVG Volume (30 Days) | 166.5K | ★ 495.7K |
| Earning Date | 03-12-2026 | 03-19-2026 |
| Dividend Yield | ★ 16.12% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.68 | N/A |
| Revenue | ★ $48,857,628.00 | N/A |
| Revenue This Year | $15.98 | N/A |
| Revenue Next Year | $1.33 | N/A |
| P/E Ratio | $6.94 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $11.22 | $0.99 |
| 52 Week High | $15.20 | $7.25 |
Technical Indicators
Market Signals| Indicator | REFI | ZURA |
|---|---|---|
| Relative Strength Index (RSI) | 32.82 | 46.65 |
| Support Level | N/A | $5.62 |
| Resistance Level | $12.59 | $6.99 |
| Average True Range (ATR) | 0.32 | 0.51 |
| MACD | -0.10 | -0.06 |
| Stochastic Oscillator | 17.95 | 36.51 |
Price Performance
Historical ComparisonAbout REFI Chicago Atlantic Real Estate Finance Inc.
Chicago Atlantic Real Estate Finance Inc is engaged in a commercial real estate finance company. Its primary investment objective is to provide attractive risk-adjusted returns for stockholders over time, through consistent current income dividends and other distributions and secondarily through capital appreciation.
About ZURA Zura Bio Limited
Zura Bio Ltd is a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases. It is developing three assets which have completed Phase I/Ib studies and are Phase II ready. It is developing a portfolio of therapeutic indications for tibulizumab and torudokimab with a goal of demonstrating their efficacy, safety, and dosing convenience in autoimmune and inflammatory diseases.